Joseph Merola
Dermatology · Dallas, TXNPI 1881807469
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $940,780 of the $1,162,527 with a category attached, or 80.9%. It is spread thinly across 36 manufacturers, the largest accounting for just 16.0%. Among dermatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,111 payments — averaging $1046.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$186K
- Novartis$125K
- Sanofi$107K
- Eli Lilly$96K
- AbbVie$89K
- UCB SA$68K
- plus $490K from 30 others
Across 280 payments — averaging $4251.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$195K
- Amgen$179K
- Regeneron$152K
- Novartis$107K
- Pfizer$100K
- UCB SA$92K
- plus $367K from 12 others
What the payments were for
- Consulting fees$940,78081%
- Speaking & faculty fees$110,0589%
- Travel & lodging$80,1947%
- Food & beverage$18,0132%
- Education$13,4821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 167 | $186,429 |
| Novartis | 135 | $124,827 |
| Sanofi | 39 | $107,297 |
| Eli Lilly | 32 | $96,161 |
| AbbVie | 143 | $89,487 |
| UCB SA | 48 | $68,495 |
| Amgen | 98 | $67,121 |
| Novartis Pharma AG | 18 | $50,820 |
| Johnson & Johnson | 81 | $50,752 |
| UCB, Inc. | 48 | $47,380 |
| Boehringer Ingelheim | 21 | $31,474 |
| LEO Pharma Inc. | 8 | $30,790 |
| Janssen Global Services, LLC | 31 | $28,898 |
| Sun Pharmaceutical Industries Inc. | 9 | $24,156 |
| Pfizer | 10 | $21,154 |
| Biogen | 12 | $19,412 |
| Boehringer Ingelheim International GmbH | 57 | $18,064 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $15,388 |
| LEO Pharma AS | 34 | $12,906 |
| Bristol Myers Squibb | 40 | $11,016 |
| Merck | 2 | $9,500 |
| Sanofi-aventis U.S. LLC | 9 | $8,521 |
| Janssen Scientific Affairs, LLC | 10 | $8,099 |
| Astrazeneca UK Limited | 8 | $8,055 |
| GSK | 2 | $6,600 |
| EMD Serono, Inc. | 3 | $4,125 |
| AstraZeneca | 4 | $3,023 |
| Galderma Laboratories, L.p. | 6 | $2,738 |
| Arcutis Biotherapeutics, Inc. | 5 | $2,414 |
| Argenx US, Inc. | 2 | $2,280 |
| Gilead | 3 | $2,275 |
| Sanofi US Services Inc. | 1 | $1,464 |
| Janssen Research & Development, LLC | 5 | $999 |
| Incyte Corporation | 5 | $325 |
| Regeneron Healthcare Solutions, Inc. | 1 | $50 |
| Lilly USA, LLC | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COSENTYX$103,058
- Tremfya$84,189
- DUPIXENT$65,617
- Otezla$39,935
- TALTZ$37,708
- Enbrel$27,843
- Bimzelx$26,931
- AIN457A_COSENTYX_DERMATOLOGY$25,329
- Skyrizi$21,150
- ILUMYA$20,419
- Rinvoq$14,100
- SPEVIGO$13,533
- LITFULO$9,750
- OLUMIANT$9,558
- XELJANZ$9,200
- SAPHNELO$8,055
- ILARIS$7,560
- Humira$6,300
- SECUKINUMAB_COSENTYX_DERMATOLOGY$4,500
- NEMLUVIO$2,601
How this compares
$1,162,527 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 25 | $178,433 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 11 | $161,141 |
| OtezlaApremilast | 20 | $96,864 |
| Dupixent PenDupilumab | 20 | $68,881 |
| Clobetasol Propionate | 38 | $1,595 |
| ValacyclovirValacyclovir Hcl | 22 | $347 |
| Triamcinolone Acetonide | 16 | $296 |
| Ketoconazole | 21 | $270 |
| Minoxidil | 17 | $138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $67,121 | $96,86420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,098 dermatology providers in Texas.
Other dermatology in Dallas
- Jennifer CatherDallas$1.3M
- Ross RaduskyDallas$1.2M
- So Yeon PaekDallas$812K
- Martin MenterDallas$512K
- Mary HornerDallas$448K
- Donald GlassDallas$347K
- William AbramovitsDallas$325K
- Mary FleischliDallas$153K
- Adean KingstonDallas$141K
- Edward LainAustin$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.